Studying TAK-243 in Patients With Advanced Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) and in patients with lymphoma. TAK-243 is a drug that binds to and inhibits the ubiquitin-activating enzyme, an enzyme that is more active on cancer cells than healthy cells, inhibiting tumor cell proliferation and survival.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznany zaawansowany rak z przerzutami lub powracający rak, u którego poprzednie standardowe leczenie nie zadziałało
- •Pacjenci z agresywnym chłoniakiem, którzy otrzymali co najmniej 2 poprzednie leczenia i nie mają innych opcji leczenia
- •Wiek 18 lat lub więcej
- •Generalnie dobry stan zdrowia (ocena wydolności ECOG poniżej 2)
- •Prawidłowe wyniki badań krwi: hemoglobina, liczba białych i płytek krwi
- •Prawidłowa funkcja wątroby i nerek
- •Przerwa co najmniej 4 tygodnie od poprzedniego leczenia
- •Dla kobiet: menopauza lub metody antykoncepcji
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, United States
Trial contact
Site Public Contact
Sarah Shin
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.